How I treat cardiovascular complications in patients with lymphoid malignancies
| العنوان: | How I treat cardiovascular complications in patients with lymphoid malignancies |
|---|---|
| المؤلفون: | Thomas M. Habermann, Kristen B. McCullough, Joerg Herrmann |
| المصدر: | Blood |
| بيانات النشر: | American Society of Hematology, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | medicine.medical_specialty, Managing Complications in Patients with Lymphoid Cancer, Heart Diseases, medicine.medical_treatment, Immunology, Psychological intervention, Cardiomyopathy, Cancer therapy, Hematopoietic stem cell transplantation, Biochemistry, Neoplasms, medicine, Humans, Anthracyclines, In patient, Intensive care medicine, business.industry, Hematopoietic Stem Cell Transplantation, Cancer, Cell Biology, Hematology, medicine.disease, Radiation therapy, Heart failure, Cardiomyopathies, business |
| الوصف: | The prognosis of several lymphoid malignancies has improved through development of novel therapies, combination with traditional chemotherapies, and delineation of appropriate therapeutic sequencing. Toxicities that are arising because of prolonged or multiple sequential therapeutic interventions are becoming increasingly impactful. Among the broad spectrum of complications that patients with lymphoid malignancies may experience, cardiovascular toxicities are significant in terms of morbidity and mortality. The entire cardiovascular system can be affected, but cardiomyopathy, heart failure, and arrhythmias remain of greatest concerns with the use of anthracyclines, hematopoietic stem cell transplantation, and radiation therapy in patients with lymphoid malignancies. These aspects will be covered in this article within the framework of case-based discussions. Key to the management of cardiovascular complications in patients with lymphoid malignancies is awareness and preparedness across the cancer continuum. Baseline risk stratification helps to direct surveillance and early intervention efforts before, during, and after cancer therapy, which are paramount for the best possible outcomes. Along these lines, the overall goal is to enable the best possible therapies for lymphoid malignancies without the complications of clinically significant cardiovascular events. |
| تدمد: | 1528-0020 0006-4971 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3cf1d55feee217e0718c1370f0a56e9Test https://doi.org/10.1182/blood.2019003893Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....b3cf1d55feee217e0718c1370f0a56e9 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15280020 00064971 |
|---|